Scopus BioPharma Overview
Scopus BioPharma is a biopharmaceutical company developing transformational therapeutics targeting serious diseases with significant unmet medical needs. The companys lead development program, CO-sTiRNA, is a novel targeted immuno-oncology gene therapy for the treatment of multiple cancers. Its second lead development program, MRI-1867, is a peripherally restricted dual-action cannabinoid-1, or CB1, receptor inverse agonist and inhibitor of inducible nitric oxide synthase, or iNOS. Strategic partners of Scopus BioPharma include City of Hope, the National Institutes of Health, and Hebrew University, including their respective scientists, medical doctors, and other senior researchers.
Latest News
No news articles.
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | Undisclosed |
| Last funding | Undisclosed |
| Stage | — |
| Rounds | — |
| Investors | — |
Team Members
0
Web & Social Links
| Website | scopusbiopharma.com/ |
Photos & Videos
No files yet
Scopus BioPharma Business
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentTarget Customer
Healthcare & Life SciencesLife SciencesPharmaceuticalsCore Technology
BiologicalsGenesScopus BioPharma Financials
Scopus BioPharma Lifecycle
Scopus BioPharma News
0 articlesNo news articles.
Scopus BioPharma Team
No team members listed.
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 8 classification IDs that could be used for matching.
Scopus BioPharma Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 89/100 |
| Missing | video or image, markets, not claimed |
| Last update | 2022-11-03T00:00:00.000Z |
| Hidden | Pending approval (visible: 0) |